In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance-Reference-Cited by-同舟云学术

In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance

Published:2002-06 Issue:6 Volume:40 Page:2228-2230
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Bachmann Stefano P.¹,Patterson Thomas F.¹,López-Ribot José L.¹

Affiliation:

1. Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Centers for Biology in Medicine, San Antonio, Texas 78245

Abstract

ABSTRACT Caspofungin inhibits the synthesis of 1,3-β- d -glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 μg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.40.6.2228-2230.2002

Reference12 articles.

1. Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis.18:302-304.

2. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

3. Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis.32:33-37.

4. Muller, F. M., M. Weig, J. Peter, and T. J. Walsh. 2000. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother.46:338-340.

5. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards Wayne Pa.

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review;Antibiotics;2023-03-18

2. The Small Ras Superfamily GTPase Rho4 of the Maize Anthracnose Fungus Colletotrichum graminicola Is Required for β-1,3-glucan Synthesis, Cell Wall Integrity, and Full Virulence;Journal of Fungi;2022-09-22

3. Molecular Identification and Caspofungin Susceptibility Profile in Comparison to Oregano Antifungal Effects on Oral Candida Isolates;Annals of Military and Health Sciences Research;2022-03-13

4. Resistance to Antifungal Drugs;Infectious Disease Clinics of North America;2021-06

5. Antifungal Drugs;Burger's Medicinal Chemistry and Drug Discovery;2021-04-27